Investors drawn to healthcare as a defensive sector have two meaningfully different options on the table: XLV, the broad-market Health Care Select Sector SPDR Fund, and IHE, the iShares U.S. Pharmaceuticals ETF. They share a sector but not much else – different holdings, different costs, and over the past year, different results.
What Each Fund Actually Holds
XLV tracks the Health Care Select Sector Index, pulling from the S&P 500’s healthcare constituents. That means exposure across hospitals, insurers, biotech firms, medical device makers, and drug companies – a wide net that captures the full range of how healthcare generates revenue in the United States. No single corner of the industry dominates the fund’s return profile in any given year.
IHE takes a narrower path. The iShares U.S. Pharmaceuticals ETF concentrates specifically on pharmaceutical companies, cutting out the insurers, the device makers, and the hospital operators that give XLV its breadth. For an investor who wants a direct bet on drug pricing, pipelines, and patent cycles, IHE delivers that exposure without dilution from other healthcare segments.
The difference in scope shows up in how the two funds performed over the past year. IHE’s pharma-focused portfolio delivered higher returns than XLV during that period – a stretch when pharmaceutical stocks outpaced the broader healthcare sector. That outperformance reflects a narrower mandate working in investors’ favor, at least for that window. A concentrated fund that bets right wins bigger. The same logic applies when it bets wrong.
Concentration is the defining risk with IHE. When drug stocks face political pressure over pricing, or when a major pipeline drug fails a late-stage trial, a pharma-only ETF absorbs that shock fully. XLV, by contrast, can offset weakness in one healthcare segment with strength in another. That structural cushion matters more in volatile policy environments, where a single regulatory headline can move an entire sub-industry.
Expense Ratios and the Long Math
XLV carries a much lower expense ratio than IHE. That gap, while it may appear minor on an annual basis, compounds over time in ways that materially affect total returns. An investor holding either fund for a decade doesn’t just pay the expense ratio once – they pay it every year, on a growing asset base, in a way that quietly reduces compounding. Lower-cost funds start with a structural advantage that has nothing to do with stock selection.
The expense ratio difference also shifts the calculus on performance. IHE produced better one-year returns, but a portion of that outperformance gets consumed by higher fees. If the return gap between the two funds narrows in a given year – or reverses, as it can when pharmaceutical stocks underperform – the cost disadvantage of IHE becomes the dominant factor in which fund actually puts more money in an investor’s pocket.
This is where time horizon becomes the deciding variable. A trader rotating in and out of sector ETFs over months may find the fee difference negligible compared to the potential return delta. A long-term, buy-and-hold investor compounding over 15 or 20 years faces a different calculation entirely. For that investor, XLV’s lower expense ratio is a permanent tailwind. IHE’s narrower focus has to keep delivering above-average returns just to break even on costs.
One-year performance comparisons in any sector fund deserve skepticism. Healthcare sub-sectors rotate leadership frequently – pharma outperforms in some cycles, biotech in others, managed care in others. A single year of IHE beating XLV doesn’t establish a durable pattern; it reflects which corner of healthcare was rewarded during a specific twelve-month window. Building a portfolio around recent outperformance in a concentrated fund is one of the more reliable ways to buy high.
What’s worth noting is that XLV’s broader construction makes it more benchmarkable against other large-cap equity funds. It behaves, in many ways, like a sector slice of the S&P 500 – predictable, diversified within its mandate, and easy to size alongside other holdings. IHE introduces more idiosyncratic risk, which demands more active monitoring. That’s not inherently a problem, but it’s a cost of a different kind – the time and attention required to track a fund that can move sharply on drug-specific news.
Which Investor Each Fund Actually Fits
The right choice between XLV and IHE depends less on which fund looks better in a rearview mirror and more on what role healthcare is supposed to play in a given portfolio. IHE suits investors who have a specific view on pharmaceutical stocks – who believe drug companies are positioned for outperformance based on pipeline strength, patent cliffs resolving favorably, or pricing dynamics shifting in the industry’s direction. That’s an active thesis requiring conviction.
XLV suits investors who want healthcare exposure without needing to take a position on which sub-sector wins. It’s a simpler tool, cheaper to hold, and less likely to surprise in either direction. For a long-term portfolio where healthcare is a diversification play rather than a tactical bet, the lower expense ratio and broader holdings make XLV the default with a stronger case. The question an investor in IHE has to keep answering is whether the pharma-specific thesis still holds – and that’s a question that doesn’t go away after the initial buy.
